✦ LIBER ✦

Allogeneic stem-cell transplantation in patients with AML and MDS using myeloablative versus reduced-intensity doses of intravenous busulfan (Busulfex): The role of dose intensity

✍ Scribed by A. Shimoni; M. Yeshurun; I. Hardan; A. Avigdor; N. Shem-Tove; I. Ben-Bassat; A. Nagler

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Allogeneic hematopoietic stem-cell trans

✍ Shimoni, A; Hardan, I; Shem-Tov, N; Yeshurun, M; Yerushalmi, R; Avigdor, A; Ben- 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 125 KB

Phase II Trial of Reduced Intensity Busu

✍ Chen, Yi-Bin; Li, Shuli; Del Rio, Candice; Coughlin, Erin; Ballen, Karen K.; Cut 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Increasing the Dose of Busulfan Results

✍ Y.-B. Chen; L. Sun; H. Kim; E.P. Alyea; P. Armand; E.C. Attar; K.K. Ballen; C. C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Survival Advantage for Patients with AML

✍ Shimoni, Avichai; Shem-Tov, Noga; Volchek, Yulia; Danylesko, Ivetta; Yerushalmi, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Evaluation Of Busulfan's Dose-Intensity

✍ M. Hamadani; M. Craig; J. Abraham; W. Tse; A. Cumpston; C.J. Stotler; S.C. Remic 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Allogeneic Hematopoietic Stem Cell Trans

✍ A. Shimoni; N. Shem-Tov; A. Rand; Y. Volchek; R. Yerushalmi; I. Hardan; A. Nagle 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB